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Abstract
This study describes coagulase-negative staphylococcal (CoNS) infective endocarditis (IE)
epidemiology at our institution, the antibiotic susceptibility profile, and the influence of van-
comycin minimum inhibitory concentration (MIC) on patient outcomes. One hundred and
three adults with definite IE admitted to an 850-bed tertiary care hospital in Barcelona from
1995-2008 were prospectively included in the cohort. We observed that CoNS IE was an
important cause of community-acquired and healthcare-associated IE; one-third of patients
involved native valves. Staphylococcus epidermidis was the most frequent species,
methicillin-resistant in 52% of patients. CoNS frozen isolates were available in 88 patients.
Vancomycin MICs of 2.0 μg/mL were common; almost all cases were found among S. epi-
dermidis isolates and did not increase over time. Eighty-five patients were treated either
with cloxacillin or vancomycin: 38 patients (Group 1) were treated with cloxacillin, and 47 re-
ceived vancomycin; of these 47, 27 had CoNS isolates with a vancomycin MIC <2.0 μg/mL
(Group 2), 20 had isolates with a vancomycin MIC2.0 μg/mL (Group 3). One-year mortali-
ty was 21%, 48%, and 65% in Groups 1, 2, and 3, respectively (P=0.003). After adjusting for
confounders and taking Group 2 as a reference, methicillin-susceptibility was associated
with lower 1-year mortality (OR 0.12, 95% CI 0.02-0.55), and vancomycin MIC2.0 μg/mL
showed a trend to higher 1-year mortality (OR 3.7, 95% CI 0.9-15.2; P=0.069). Other in-
dependent variables associated with 1-year mortality were heart failure (OR 6.2, 95%
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CI 1.5-25.2) and pacemaker lead IE (OR 0.1, 95%CI 0.02-0.51). In conclusion, methicillin-
resistant S.epidermidis was the leading cause of CoNS IE, and patients receiving vancomy-
cin had higher mortality rates than those receiving cloxacillin; mortality was higher among
patients having isolates with vancomycin MICs2.0 μg/mL.
Introduction
Coagulase-negative staphylococci (CoNS) have come to be recognized as important, commonly
isolated pathogens [1,2]. Infections are usually associated with healthcare settings and occur in
patients harbouring indwelling polymer or metallic devices [3]. CoNS cause>10% of all infec-
tive endocarditis (IE) cases [4] and are among the most frequent etiological agents of intracardi-
ac prosthetic device infections, such as prosthetic valve endocarditis (PVE) and intracardiac
device (ICD) endocarditis [5–7]. In addition, these microorganisms are becoming an important
cause of native valve endocarditis (NVE) [8]. Among CoNS species, Staphylococcus lugdunensis
is notable for its particular virulence [9].
Resistance to methicillin and other antibiotics is becoming more frequent among CoNS.
A glycopeptide, such as vancomycin, is the recommended treatment for methicillin-resistant
CoNS (MR-CoNS) NVE, while gentamicin and rifampin are typically added in PVE [10]. The
emergence of CoNS with reduced susceptibility to vancomycin [3], together with the increasing
prevalence of glycopeptide-intermediate Staphylococcus epidermidis (GISE) [11] and resistance
to rifampin and gentamicin among methicillin-resistant S. epidermidis (MRSE), limits thera-
peutic options and warrants investigation of alternative bactericidal agents.
Among patients with Staphylococcus aureus bacteremia, increased vancomycin minimum
inhibitory concentrations (MICs) have been associated with clinical failures [12], while vanco-
mycin MICs>1 μg/mL have been associated with higher mortality [13]. There currently are no
data regarding the influence of vancomycin MIC on the outcome of CoNS IE.
This study aimed to characterize the epidemiology, clinical characteristics, and antibiotic
susceptibility pattern of CoNS IE, and the influence of methicillin susceptibility and vancomy-
cin MIC on outcomes.
Methods
This prospective cohort study was performed in an urban tertiary care hospital with 850 beds
in Barcelona, Spain. All consecutive CoNS IE patients seen from 1995 to 2008 were recorded in
a database using a standardized case report form. Only patients with a definite diagnosis of IE
[14] were included. All survivors were followed1 year. The Ethics Committee of our institu-
tion gave its approval to perform the current study.
The variables analyzed, including age, gender, history of chronic disease, calendar year,
right- vs. left-sided IE, type of endocarditis (NVE, PVE, or ICD-associated), place of acquisi-
tion (community-acquired, nosocomial, or non-nosocomial healthcare-associated) [15], clini-
cal complications (heart failure, renal failure, or systemic emboli, including stroke), need for
surgery, and in-hospital and 1-year mortality, have been previously defined [16].
Due to the duration of the study period, antimicrobial treatment for CoNS IE was given ac-
cording to the 1995 (originally) and 2005 (later) American Heart Association (AHA) recom-
mendations [10,17], both of which recommend the same agents for CoNS IE. Methicillin-
susceptible CoNS (MS-CoNS) IE was treated with cloxacillin, and MR-CoNS IE was treated
with either vancomycin alone (NVE) or combined with other antibiotics (PVE or ICD IE). The
CoNS IE and Vancomycin MIC
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decision of using monotherapy or combination was at the discretion of the treating physician
and influenced by factors related to patient’ clinical status (ie, renal function, drug allergy, po-
tential drug interactions, comorbidity, age). Per guidelines of the time [10,17], a vancomycin
trough concentration of 10–15 μg/mL was targeted.
In order to analyze the impact of methicillin resistance and vancomycin MIC on outcomes,
we divided patients into 3 groups: patients treated with cloxacillin for MS-CoNS IE (Group 1),
vancomycin for CoNS with vancomycin MIC<2 μg/mL (Group 2), or vancomycin for CoNS
with vancomycin MIC2 μg/mL (Group 3). In the event of polyclonal or polymicrobial CoNS
IE, we categorized patients per the higher vancomycin MIC.
Identification of CoNS Isolates
Isolates were stored at -80°C in skim milk. Isolates were identified using the API ID 32 Staph
(bioMérieux, Marcy l'Etoile, France). Species were divided into 4 groups: S. epidermidis, S. lug-
dunensis, other CoNS, and polymicrobial IE. Polymicrobial infections were caused by different
CoNS isolates. Polyclonal CoNS infections were caused by2 isolates of the same species with
different antibiotic susceptibilities and each isolate was counted separately.
Antibiotic Susceptibility Testing
Susceptibility was determined by Etest according to the manufacturer’s recommendations
(AB Biodisk-bioMérieux, Marcy l'Etoile, France). Etest strips were purchased from bioMérieux
(Madrid, Spain). The following antimicrobials were evaluated: penicillin, oxacillin, erythromy-
cin, clindamycin, gentamicin, ciprofloxacin, cotrimoxazole, rifampin, vancomycin, teicoplanin,
linezolid, and daptomycin. The latter 2 agents were tested retrospectively after they became
available and with emerging data about the impact of elevated vancomycin MICs. S. aureus
ATCC 29213 was used as the test control strain. For vancomycin, isolates were divided accord-
ing to MIC (<2 μg/mL or2 μg/mL).
Statistical Analyses
Categorical variables were summarized as percentages and compared using the Chi-square
or Fisher’s exact test. Continuous variables were summarized as mean and SD. The Mantel-
Haenszel test for trend was used if there were significant differences in vancomycin MIC over
time among the isolates. The Kaplan-Meier estimator was used for survival analysis, and
curves were compared using the log-rank test. For logistic regression analysis, predictors with
a P<0.30 were included, and it was performed by a likelihood ratio-based backward exclusion
method. A 2-sided P<0.05 was considered to be statistically significant. All statistics were cal-
culated with SPSS statistical package version 16.0 (SPSS, Inc., Chicago, IL, USA).
Results
Clinical Characteristics of CoNS IE
There were 103 patients with CoNS IE during the study, representing 16% of the 620 IE cases
diagnosed at our institution (Fig 1). Regarding the type of IE, 36 (35%) were ICD-associated,
31 (30%) were PVE, and 36 (35%) were NVE. Stored CoNS isolates were available for 88 pa-
tients, in whom 98 isolates were identified. Isolates could not be obtained in the others due to
transfer from another institution.
The clinical characteristics and outcomes of these 103 patients are summarized by type of en-
docarditis in Table 1. The majority of infections were due to S. epidermidis, while the species was
not identified in 15 (15%) patients. In 59 (57%) patients, isolates were susceptible to methicillin,
CoNS IE and Vancomycin MIC
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with a lower rate in PVE (36%) compared with NVE (61%) or ICD IE (72%) (P = 0.009). The
aortic valve was most commonly involved, but 13 (13%) patients had involvement of multiple
valves. While vegetations were present in 82 (80%) patients, only 13 (13%) patients had evidence
of systemic emboli. Median vegetation size was greatest in ICD IE (P = 0.007); perivalvular ab-
scesses were most common among patients with PVE (P<0.001). Sixty-six patients (64%) re-
quired surgery, including almost all patients with ICD IE. Mortality rates were similar within the
NVE and PVE groups and lowest among patients with ICD IE (P<0.001).
The clinical characteristics and outcomes of the 88 patients with available isolates are sum-
marized by CoNS species in S1 Table. In-hospital and 1-year mortality rates were similar
among groups but were highest among patients infected with S. lugdunensis (55% for both).
CoNS Identification and Antibiotic Susceptibility Patterns
Ninety-eight isolates were identified in 88 patients: 70 S. epidermidis (71%), 11 S. lugdunensis
(11%), 10 S. hominis (10%), and 7 other species (S2 Table). There were 6 and 4 patients with
polymicrobial and polyclonal IE, respectively.
Susceptibility data are presented in S2 Table. Overall, 44% of the CoNS isolates were methicillin-
-resistant, including 51% of S. epidermidis. One-third of MRSE also were resistant to gentamicin, ri-
fampin, and ciprofloxacin. All isolates of S. lugdunensis remained methicillin-susceptible.
Forty-two isolates had a vancomycin MIC2 μg/mL (35 isolates at 2 μg/mL, 5 isolates at
3 μg/mL, and 2 isolates at 4 μg/mL). By species, 47% of the S. epidermidis isolates and 7% of
other species (P<0.001) had vancomycin MICs of 2 μg/mL. The clinical, microbiological and
therapeutic characteristics, as well as the outcomes, of the 39 patients with strains with vancomy-
cin MIC2 μg/mL can be seen in S3 Table. Two S. epidermidis isolates (both with vancomycin
Fig 1. Patient disposition. Abbreviations: IE, infective endocarditis; NV, native valve; PV, prosthetic valve;
CoNS, coagulase-negative staphylococci.
doi:10.1371/journal.pone.0125818.g001
CoNS IE and Vancomycin MIC
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Table 1. Clinical characteristics and outcome of 103 consecutive patients with IE due to CoNS, according to the type of endocarditis (1995–2008).
NVE (N = 36) PVE (N = 31) ICD IE (N = 36) P value
Mean age (SD), y 61.8 (16.7) 60.7 (11.3) 62.1 (19.4) 0.506
Male gender 27 (75) 24 (77) 30 (83) 0.676
Year of diagnosis 0.560
1995–1999 13 (36) 9 (29) 9 (25)
2000–2004 14 (39) 9 (29) 15 (42)
2005–2008 9 (25) 13 (42) 12 (33)
CoNS speciesa 0.400
S. epidermidis 17 (47) 18 (58) 25 (69)
S. lugdunensis 4 (11) 2 (7) 5 (14)
Other CoNSb 4 (11) 4 (13) 3 (8)
Polymicrobial 4 (11) 1 (3) 1 (3)
Unknown 7 (20) 6 (19) 2 (6)
Methicillin susceptibility 22 (61) 11 (36) 26 (72) 0.009
Predisposing conditions and underlying diseases
Diabetes mellitus 1 (3) 8 (26) 4 (11) 0.015
Chronic renal failure 4 (11) 2 (7) 1 (3) 0.386
Hemodialysis 4 (11) 0 0 0.034
History of cancer 4 (11) 5 (16) 2 (6) 0.239
HIV infection 1 (3) 0 0 1.000
Chronic liver disease 9 (25) 3 (10) 2 (6) 0.036
Chronic lung disease 0 2 (7) 3 (8) 0.267
Transplantation 1 (3) 0 0 1.000
Presumed mode of acquisition 0.004
Nosocomial 11 (31) 4 (13) 6 (17)
Non-nosocomial health care associated 11 (31) 18 (58) 7 (19)
Community acquired 14 (39) 9 (29) 23 (64)
Valve involvement <0.001
Aortic 14 (39) 12 (39) 1 (3)c
Mitral 13 (36) 11 (36) 0
Tricuspid 1 (3) 1 (3) 3 (8)c
PCM/ICD wirec 0 0 34 (94)
Unknown 1 (3) 1 (3) 0
Mitral + aortic 4 (11) 5 (16) 0
Tricuspid + aortic 2 (6) 0 0
Tricuspid + aortic + mitral 1 (3) 1 (3) 0
Echocardiographic ﬁndings
Presence of vegetations 31 (86) 25 (81) 26 (72) 0.338
Vegetation size in mm, median (IQR) 10 (7–15) 10 (6.5–15.5) 20 (10–25) 0.007
Perivalvular abscess 4 (11) 15 (48) 0 <0.001
Complications
Heart failure 15 (42) 11 (36) 0 <0.001
Renal failure 20 (56) 18 (58) 4 (11) <0.001
Systemic emboli 4 (11) 9 (29) 0 0.001
Antibiotic treatment 0.098
Cloxacillin alone 1 (3) 1 (3) 6 (17)
Cloxacillin in combinationd 13 (36) 8 (26) 16 (44)
Vancomycin alone 4 (11) 5 (16) 3 (8)
Vancomycin in combinationc 15 (42) 16 (52) 11 (31)
Other antibioticse 3 (8) 1 (3) 0
(Continued)
CoNS IE and Vancomycin MIC
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MICs of 3 μg/mL) demonstrated intermediate resistance to teicoplanin (MIC 16 μg/mL). We did
not find any isolates with intermediate susceptibility to vancomycin. Vancomycin MIC did not
show a trend towards increase over time for overall CoNS isolates (P = 0.49) nor for S. epidermi-
dis specifically (P = 0.25); this pattern did not change according to methicillin susceptibility. All
isolates remained linezolid- and daptomycin-susceptible, but 1 strain each of S. epidermidis and
S. capitis had daptomycin MICs of 1.5 μg/mL. Regarding other recommended antibiotics for
PVE, we found that 14/31 (45%) of the CoNS isolates in patients with PVE were resistant to gen-
tamicin, rifampin and/or ciprofloxacin.
Impact of Methicillin Susceptibility and Vancomycin MIC on Outcomes
Three of the 88 patients were excluded from the assessment of outcome because they were not
treated with either cloxacillin or vancomycin, but instead were treated with teicoplanin (2) and
linezolid (1). Cloxacillin was used in 38 (45%) patients (Group 1), and vancomycin was used in
47 (55%). Twelve of these 47 (26%) patients with MS-CoNS were treated with vancomycin be-
cause of penicillin allergy (3) or medical decision (9). Of these 12 patients, 2 died (17%).
Among patients treated with vancomycin, 27 (32%) had CoNS isolates with vancomycin
MICs<2 μg/mL (Group 2) and 20 (24%) had MICs2 μg/mL (Group 3). The main clinical
characteristics of the 3 groups are presented in Table 2.
In-hospital mortality was higher among those patients treated with vancomycin, regardless
of vancomycin MIC, than in those treated with cloxacillin (47% vs 18%; P = 0.012). In-hospital
mortality was 18%, 44%, and 50% for Groups 1, 2, and 3, respectively (P = 0.021), and 1-year
mortality was 21%, 48%, and 65%, respectively (P = 0.003). Mortality was similar for patients
treated with cloxacillin regardless of vancomycin MIC (Fig 2). Conversely, the highest mortali-
ty was among vancomycin-treated patients infected with CoNS isolates having vancomycin
MICs2 μg/mL (P = 0.007). One-year survival analysis according to the treatment received
and vancomycin MIC is presented in Fig 3.
Table 3 shows the univariate and multivariate analyses of risk factors associated with one-year
mortality. Using the group of patients with MR-CoNS IE with vancomycin MICs<2 μg/mL
treated with vancomycin (Group 2) as the reference, Group 1 (MS-CoNS IE treated with cloxa-
cillin) and Group 3 (MR-CoNS IE with vancomycin MICs2 μg/mL) respectively had indepen-
dently lower and higher mortality (OR 0.12, 95% CI 0.02–0.55 and OR 3.7, 95% CI 0.9–15.2,
Table 1. (Continued)
NVE (N = 36) PVE (N = 31) ICD IE (N = 36) P value
Outcome
Surgical treatment 11 (31) 22 (71) 33 (92) <0.001
In-hospital mortality 16 (44) 14 (45) 2 (6) <0.001
1-year mortality 20 (56) 16 (52) 3 (8) <0.001
Unless otherwise noted, all values are shown as n (%). Abbreviations: CoNS, coagulase-negative staphylococci; HIV, human immunodeﬁciency virus;
ICD, intracardiac device; IE, infective endocarditis; IQR, interquartile range; NVE, native valve endocarditis; PCM/ICD, pacemaker/implantable
cardioverter-deﬁbrillator; PVE, prosthetic valve endocarditis; SD, standard deviation.
aOnly 88 patients had available isolates; these 88 patients served as the basis for the rest of the study (see Fig 1).
b S. hominis (7), S. capitis (2), S. schleiferi (2).
cPCM/ICD wire endocarditis was associated with tricuspid vegetations in 3 patients and aortic vegetations in 1 case.
dAdministration of a second antibiotic, with or without a third, together with cloxacillin or vancomycin for >2 days.
eTwo patients received teicoplanin, 1 received imipenem, and 1 received linezolid.
doi:10.1371/journal.pone.0125818.t001
CoNS IE and Vancomycin MIC
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Table 2. Clinical characteristics of 85 patients with CoNS IE according to treatment received (cloxacillin or vancomycin).a
Treated with vancomycin
Treated with
cloxacillin (N = 38)
Vancomycin MIC <2
(N = 27)
Vancomycin MIC 2
(N = 20)
P
value
Mean age, y 68.5 (55–77) 66.0 (59–73.5) 60.5 (44.5–72.5) 0.182
Male gender 28 (74) 20 (74) 17 (85) 0.645
CoNS species 0.471
S. epidermidis 22 (58) 19 (70) 16 (80)
S. lugdunensis 7 (18) 4 (15) 0
Other 6 (16) 3 (11) 2 (10)
Polymicrobialb 3 (8) 1 (4) 2 (10)
Predisposing conditions and
underlying diseases
Diabetes mellitus 3 (8) 3 (11) 4 (20) 0.387
Chronic renal failure 2 (5) 2 (7) 2 (10) 0.865
Hemodialysis 2 (5) 1 (4) 0 0.792
History of cancer 4 (11) 1 (4) 4 (20) 0.184
HIV infection 0 1 (4) 0 0.553
Chronic liver disease 2 (5) 3 (11) 5 (25) 0.090
Chronic lung disease 1 (3) 3 (11) 0 0.168
Transplantation 0 1 (4) 1 (5) 0.500
History of IE 1 (3) 0 1 (5) 0.713
Presumed mode of acquisition 0.080
Nosocomial 5 (13) 7 (26) 6 (30)
Non-nosocomial healthcare
associated
11 (29) 8 (30) 10 (50)
Community acquired 22 (58) 12 (44) 4 (20)
Type of endocarditis, n (%) 0.109
NV 11 (29) 10 (37) 7 (35)
PV 7 (18) 8 (30) 9 (45)
Pacemaker lead 20 (53) 9 (33) 4 (20)
Valve involvement 0.301
Aortic 6 (16) 9 (33) 7 (35)
Mitral 8 (21) 4 (15) 4 (20)
Tricuspid 0 0 1 (5)
PCM/ICD wire 20 (53) 9 4 (20)
Unknown 0 1 (4) 1 (5)
Mitral + aortic 4 (11) 2 (7) 2 (10)
Tricuspid + aortic 0 1 (4) 0
Tricuspid + aortic + mitral 0 1 (4) 1 (5)
Echocardiogra-phic ﬁndings
Presence of vegetations 28 (74) 22 (82) 18 (90) 0.350
Vegetation size in mm,
median (IQR)
10 (0–19) 10 (1–16) 8 (2.5–10) 0.881
Perivalvular abscess 5 (13) 5 (20) 5 (26) 0.436
Complications
Heart failure 9 (24) 9 (33) 5 (25) 0.670
Renal failure 11 (29) 14 (52) 10 (50) 0.129
Systemic emboli 3 (8) 1 (4) 4 (20) 0.178
(Continued)
CoNS IE and Vancomycin MIC
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respectively). Other independent variables associated with in-hospital mortality were heart fail-
ure and pacemaker lead endocarditis as a protective factor for mortality.
Discussion
Incidence, Types of IE, and Clinical Characteristics
CoNS are increasingly identified as a cause of NVE [8, 21] and caused 9% of all NVE in our
cohort. In one recent multicenter investigation, nearly 8% of all NVE not associated with in-
travenous drug use (IVDU) were caused by CoNS, predominantly S. epidermidis [8]. A recent
multinational prospective cohort study found that 16% of PVE not due to IVDU was attributed
to CoNS [6]. S. epidermidis was isolated in 82% of cases, and 67% of these were methicillin-
resistant. These results are similar to those seen in our series. In recent data provided by the
International Collaboration on Endocarditis (ICE), CoNS was shown to be the second global
cause of ICD IE immediately after S. aureus, being more often nosocomially-acquired than S.
aureus [18].
Table 2. (Continued)
Treated with vancomycin
Treated with
cloxacillin (N = 38)
Vancomycin MIC <2
(N = 27)
Vancomycin MIC 2
(N = 20)
P
value
Outcomes
Surgery 28 (74) 16 (59) 12 (60) 0.394
In-hospital mortality 7 (18) 12 (44) 10 (50) 0.021
1-year mortality 8 (21) 13 (48) 13 (65) 0.003
Unless otherwise noted, all values are shown as n (%). Abbreviations: CoNS, coagulase-negative staphylococci; HIV, human immunodeﬁciency virus; IE,
infective endocarditis; IQR, interquartile range; PCM/ICD, pacemaker/implantable cardioverter-deﬁbrillator; MIC, minimum inhibitory concentration; NV,
native valve; PV, prosthetic valve.
aThree out of the 88 patients did not receive either cloxacillin or vancomycin and were not included.
b S. hominis (7), S. capitis (2), S. schleiferi (2).
doi:10.1371/journal.pone.0125818.t002
Fig 2. One-year mortality according to antibiotic treatment and vancomycin MIC.One-year mortality
among 85 patients with coagulase-negative staphylococci infective endocarditis, according to antibiotic
therapy and vancomycin minimum inhibitory concentration (MIC).
doi:10.1371/journal.pone.0125818.g002
CoNS IE and Vancomycin MIC
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Overall, we noted 44% of CoNS isolates were methicillin-resistant, a lower rate than docu-
mented in other surveys [19–22], and we did not find an association between methicillin-
resistance and healthcare acquisition as did previous studies [8, 21]. Reduced susceptibility to
vancomycin (MIC>2 μg/mL) was found in 3% of CoNS isolates in our study, similar to a 2%
rate in a recent review of bloodstream infections caused by CoNS [23]. As was the case with
other recent summaries of susceptibility data from Spain [20–22], no CoNS isolates were resis-
tant to vancomycin, linezolid, or daptomycin.
Impact of Oxacillin Susceptibility and Vancomycin MIC on Outcome
Vancomycin treatment was associated with higher mortality, especially among patients with IE
due to isolates with vancomycin MICs2 μg/mL. A number of studies have found a correla-
tion between vancomycin MIC and poorer outcomes among patients with methicillin-resistant
S. aureus bacteremia [24]. The present study is, to our knowledge, the first to demonstrate
the same correlation between poor outcomes and vancomycin MIC in CoNS IE. This finding
could have important clinical implications In addition, it suggests an important role for alter-
native antibacterial agents. In our series, higher vancomycin MICs had no impact on outcomes
in patients with MS-CoNS IE receiving cloxacillin. In contrast, a recent study showed that
among patients with methicillin-susceptible S. aureus (MSSA) bacteremia treated with fluclox-
acillin, outcomes were less favourable among those with higher vancomycin MICs [25]. Our
group recently found the same association of high vancomycin MIC and left-sidedMSSA IE
[26]. Higher vancomycin MICs could be a marker of bad prognosis in S. aureus bacteremia
and IE regardless of the administered treatment, with the causative mechanism yet to be identi-
fied, but in light of our results, however, we cannot conclude that this hypothetical mechanism
is common to all staphylococci.
Impact of Antibiotic Treatment on Outcome
Vancomycin monotherapy is the treatment of choice for MR-CoNS NVE [10,27]. However, we
found very high mortality rates in vancomycin-treated patients. A vancomycin trough of 15–
20 μg/mL is supposed to achieve the suggested target AUC/MIC ratios of400 for organisms
with MICs1 μg/mL [28]. For patients infected with CoNS isolates having MICs2 μg/mL,
this ratio was likely not achieved in most cases; this may explain why patients with MR-CoNS
Fig 3. One-year survival analysis according to antibiotic therapy and vancomycin MIC.One-year
survival analysis of 85 patients with coagulase-negative staphylococci infective endocarditis according to the
treatment received and vancomycin minimum inhibitory concentration (MIC).
doi:10.1371/journal.pone.0125818.g003
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Table 3. Prognostic factors associated with one-year mortality in the 85 patients of CoNS endocarditis treated with either cloxacillin or
vancomycin.
Univariate analysis Multivariate analysis
One-year mortality
(N = 34)
Survived
(N = 51)
P
value
OR 95% CI P
value
Mean age (SD), y 63.5 (14.3) 62.6 (16.1) 0.795
Male gender 25 (74) 40 (78) 0.602
Year of diagnosis 0.929
1995 11 (32) 16 (31)
2000 12 (35) 20 (39)
2005 11 (32) 15 (29)
CoNS species 0.773
S. epidermidis 22 (65) 35 (69)
S. lugdunensis 6 (18) 5 (10)
Other speciesa 4 (12) 7 (14)
Polymicrobial 2 (6) 4 (8)
Predisposing conditions and
underlying diseases
Diabetes mellitus 5 (15) 5 (10) 0.733
Chronic renal failure 4 (12) 2 (4) 0.212
Hemodialysis 1 (3) 2 (4) 1.000
History of cancer 3 (9) 6 (12) 0.735
HIV infection 1 (3) 0 0.400
Chronic liver disease 8 (24) 3 (6) 0.023
Chronic lung disease 1 (3) 3 (6) 0.647
Transplantation 0 1 (2) 1.000
History of IE 1 (3) 1 (2) 1.000
Presumed mode of acquisition 0.619
Nosocomial 8 (24) 10 (20)
Non-nosocomial healthcare
associated
13 (38) 16 (31)
Community acquired 13 (38) 25 (49)
Type of endocarditis
NV 19 (56) 9 (18) <0.001 0.1 0.02–
0.51
0.006
PV 13 (38) 11 (22) 0.094
Pacemaker lead 2 (6) 31 (61) <0.001
Valve involvement
Aortic 22 (65) 12 (24) <0.001
Mitral 15 (44) 11 (22) 0.027
2 valves 8 (24) 3 (6) 0.023
Complications
Heart failure 18 (53) 5 (10) <0.001 6.2 1.5–
25.2
0.011
Renal failure 21 (62) 14 (28) 0.002
Systemic emboli 3 (9) 5 (10) 1.000
Perivalvular abscess 10 (29) 5 (10) 0.020
Surgical treatment 16 (47) 40 (78) 0.003
Treatment groups b 0.003
(Continued)
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IE with vancomycin MIC2 μg/mL had the highest mortality rates. At the time the AHA
guidelines were published, higher vancomycin troughs were not yet recommended and so were
not targeted in our patients. Nonetheless, Holmes et al [29] did not clearly find better outcomes
in patients with S. aureus bacteremia achieving an AUC/MIC ratio>400. Thus, given these re-
cent data and a lack of evidence regarding a correlation between AUC/MIC and CoNS bacter-
emia/IE outcomes, our results suggest the use of alternative agents to vancomycin.
For cases of MR-CoNS PVE, the recommended therapy is vancomycin in combination with
rifampin and gentamicin [10,27]. Interestingly, we found that 45% of the CoNS causing PVE
were resistant to at least one recommended drug associated to vancomycin (data not shown).
Thus, in our setting, it may not be unusual that empirical treatment for CoNS-PVE is inappro-
priate. Therefore, better antibiotic options are needed for CoNS PVE since deciding the most
suitable combination for CoNS PVE may result challenging in light of current evidence. Al-
though clinical data supporting the use of ceftaroline for CoNS IE is lacking, some in vitro studies
provide interesting results, showing a good susceptibility profile for ceftaroline against CoNS
that includes methicillin-resistant, linezolid-resistant and daptomycin non-susceptible strains
[30,31]. Besides, no emergence of ceftaroline-resistant strains has been described to date. Clinical
evidence also lacks for telavancin, whose in vitro activity against CoNS is better than vancomycin
due to its dual mechanism of action, which confers a rapid bactericidal activity [32, 33]. However,
increased MICs for telavancin have been reported in some strains of S. epidermidis with reduced
susceptibility to glycopeptides [33]. As occurred with the former agent, no clinical experience
with tigecycline for the treatment of CoNS IE is yet available and experimental evidence from the
IE model has been neither published. Linezolid use is limited in monotherapy due to its bacterio-
static activity. Noteworthy, emergence of resistance to linezolid among CoNS is increasingly re-
ported [34]. Results derived from both in vivo studies and clinical experience with daptomycin
are encouraging [35–38]. We have previously shown in animal models that daptomycin was a
better therapeutic option than vancomycin [35, 39], particularly for IE caused by MR-CoNS with
vancomycin MICs>1 μg/mL. Consequently, we believe that daptomycin should be considered
as the preferred alternative for patients with NVE or PVE caused by MR-CoNS.
Study Limitations
This study has several limitations. First, it is a non-randomized, observational study. Second, it
was conducted at a single, tertiary referral center for IE, so referral bias limits external validity,
Table 3. (Continued)
Univariate analysis Multivariate analysis
One-year mortality
(N = 34)
Survived
(N = 51)
P
value
OR 95% CI P
value
Cloxacillin 8 (24) 30 (59) 0.12 0.02–
0.55
0.008
Vancomycin (MIC <2 μg/mL) 13 (38) 14 (27) 1.0
Vancomycin (MIC 2 μg/mL) 13 (38) 7 (14) 3.7 0.9–
15.2
0.069
Unless otherwise noted, all values are shown as n (%). Abbreviations: CI, conﬁdence interval; CoNS, coagulase-negative staphylococci; HIV, human
immunodeﬁciency virus; IE, infective endocarditis; MIC, minimum inhibitory concentration; NV, native valve; OR, odds ratio; PV, prosthetic valve; SD,
standard deviation.
aS. hominis (7), S. capitis (2), S. schleiferi (2).
bIn the multivariable regression analysis, cloxacillin treatment is the reference category. Vancomycin MIC <2 μg/mL effect on one-year mortality is
compared to cloxacillin and Vancomycin MIC 2 μg/mL is compared to Vancomycin MIC <2 μg/mL.
doi:10.1371/journal.pone.0125818.t003
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as does the loss of some of the isolates of transferred patients. Third, while the total number of
IE cases diagnosed in our center is large, the number of documented CoNS cases is relatively
small and did not allow us to investigate the impact of vancomycin MIC in subpopulations of
interest (eg, at the species level, according to IE type). As stated above, our study lacks pharma-
cokinetic and pharmacodynamic data, especially regarding the assessment of AUC/MIC ratios.
Conclusion
CoNS are well recognized as an important cause of IE, including infections of both native and
prosthetic valves, as well as those involving pacemakers. Such infections are often acquired in
healthcare settings, and are caused increasingly by pathogens less susceptible to agents like van-
comycin that have long been standards of care. While several studies have documented poor
outcomes among vancomycin-treated patients with serious S. aureus infections caused by iso-
lates with higher vancomycin MICs, our report is the first to demonstrate a similar pattern
among patients with MR-CoNS IE. Alternatives to currently recommended drugs should be
considered in future studies. So, additional randomized, controlled studies are warranted.
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